Nicolas Mach
Papers
1
Total Citations
32
H-Index
1
About
Nicolas Mach is a leading clinical investigator in urothelial carcinoma, with a research focus on perioperative chemoimmunotherapy for muscle-invasive bladder cancer. His major contribution lies in pioneering the integration of immune checkpoint inhibitors with standard cisplatin-based chemotherapy before surgery, aiming to reduce high relapse rates in operable disease. Mach’s landmark single-arm phase II trial (SAKK 06/17) evaluated durvalumab combined with cisplatin/gemcitabine, with a preplanned interim analysis demonstrating promising safety and efficacy signals. This work, published in 2020 and cited 32 times, has helped shape the evolving landscape of neoadjuvant treatment strategies. By testing the hypothesis that PD-L1 inhibition can synergize with chemotherapy in the perioperative setting, Mach has addressed a critical unmet need in muscle-invasive urothelial carcinoma. His research continues to influence clinical trial design and offers hope for improved outcomes in patients with this aggressive malignancy.
Research Focus
Key Achievements
Top Papers
- 1